What Is Integril IV 0.75 mg/ml Indications and Uses?

Integril is indicated in- Patients with acute coronary syndrome (unstable angina/non-ST- segment elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). Patients undergoing PCI, including those undergoing intracoronary stenting.

Pharmacology (Source, Chemical and Physical Composition) Of Integril IV 0.75 mg/ml

Integril IV 0.75 mg/ml (Eptifibatide) is indicated- For the treatment of patients with acute coronary syndrome (unstable angina/non-ST-segment elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). For the treatment of patients undergoing PCI, including those undergoing intracoronary stenting.

Drug Interactions of Integril IV 0.75 mg/ml

In various clinical studies, Integril was used concomitantly with unfractionated heparin and aspirin. In another study, clopidogrel or ticlopidine were used routinely starting the day of PCI. Because Integril inhibits platelet aggregation, caution should be employed when it is used with other drugs that affect hemostasis, including thrombolytics, oral anticoagulants, NSAIDS and dipyridamole. To avoid potentially additive pharmacologic effects, concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided. Enoxaparin did not alter the pharmacokinetics of Integril.

Side Effects of Integril IV 0.75 mg/ml

Bleeding is the most common adverse effect. Adverse reactions include intracranial hemorrhage and stroke, thrombocytopenia, allergic reactions and hypotension.

Precautions And Warnings for Integril IV 0.75 mg/ml

In patients undergoing PCI, Integril Injection is associated with an increase in major and minor bleeding at the site of arterial sheath placement. Special care should be employed to minimize the risk of bleeding among these patients. If bleeding cannot be controlled with pressure, infusion of Integril and concomitant heparin should be stopped immediately. Because Integril inhibits platelet aggregation, caution should be employed when it is used with drugs that affect hemostasis, including thrombolytics, oral anticoagulants, NSAIDs, and dipyridamole. Use with other GP IIb-IIIa inhibitors should be avoided. Integril is cleared in part by the kidney and its plasma concentrations are doubled in patients with renal disease (creatinine clearance <50 ml/min). Therefore, the infusion dose of Integril needs to be reduced to 1 mcg/kg/min in these patients. Integril is contraindicated in patients who are dependent upon renal dialysis. Caution should be exercised when administering Integril to patients with a platelet count <100,000/mm3. Bleeding is the most common complication encountered during Integril therapy. The majority of excess major bleeding events were localized at the femoral artery access site. Oropharyngeal, genitourinary, gastrointestinal, and retroperitoneal bleeding were seen more commonly with Integril compared with placebo. Arterial and venous punctures, intramuscular injections, and the use of urinary catheters, nasotracheal intubation, and nasogastric tubes should be minimized. When obtaining intravenous access, noncompressible sites (e.g., subclavian or jugular veins) should be avoided. Before infusion of Integril, the following laboratory tests should be performed to identify preexisting hemostatic abnormalities: hematocrit or hemoglobin, platelet count, serum creatinine, and PT/aPTT. In patients undergoing PCI, the activated clotting time (ACT) should also be measured.

Use During Pregnancy and Lactation

Pregnancy category B. Animal studies revealed no evidence of harm to the fetus due to Integril IV 0.75 mg/ml (Eptifibatide). There are, however, no adequate and well-controlled studies in pregnant women with Eptifibatide. It is not known whether Eptifibatide is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Eptifibatide is administered to a nursing mother.

Therapeutic Class

Anti-platelet drugs

Storage Conditions of It

Vials should be stored refrigerated at 2-8°C. Vials may be transferred to room temperature storage for up to 2 months. Unused portion left in the vial should be discarded. Vials should be protected from light until administration. Pack Image: Integril 0.75 mg/ml Injection Thanks for using MedEx! How would you rate your experience so far?